We are now currently investigating the pharmacokinetic profile of the best-hit molecules in mice, with the intention of progressing to studies of disease-modifying effects in the murine G93A-SOD1 transgenic model of ALS. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.